Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson (JNJ) with an Outperform rating and $190 price target The firm expects growth names and/or “dream the dream” names to be the winners looking to 2025 and outside of Mounjaro/Zepbound from Lilly (LLY), the firm sees J&J’s Pharma growth drivers of JNJ-2113, Tremfya, nipocalimab, Carvykti, and Drazalex Faspro as “best-in-class.” Moreover, even with Stelara facing loss-of-exclusivity headwinds, Wolfe still forecasts J&J’s revenue growing at least 3%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JNJ:
- Johnson & Johnson initiated with an Outperform at Wolfe Research
- Johnson & Johnson announces results from analyses of Phase 2 DAHLIAS study
- Charter to acquire Liberty Broadband, Spotify reports Q3 beat: Morning Buzz
- J&J sues government agency over payment terms for 340B hospitals, STAT says
- Johnson & Johnson MedTech receives IDE approval for Ottava system
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
